title: Lessons from Eprex for biogeneric firms.
authors.forename: Sabine
authors.initials: S
authors.lastname: Louët
mesh_terms: D001709:Biotechnology / Q000592:standards*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000592:standards* / Q000639:trends; D016568:Drugs, Generic / Q000191:economics / Q000592:standards*; D004921:Erythropoietin / Q000592:standards*; D005062:European Union; D011358:Product Surveillance, Postmarketing / Q000592:standards* / Q000639:trends; D011994:Recombinant Proteins
chemical_list: D016568:Drugs, Generic; D011994:Recombinant Proteins; D004921:Erythropoietin